Omecamtiv Mecarbil治疗重度心力衰竭的GALACTIC-HF事后分析
该事后分析基于GALACTIC-HF随机临床试验,评估Omecamtiv Mecarbil在重度心力衰竭患者中的疗效与安全性。结果显示,重度心衰患者(占27.4%)接受Omecamtiv Mecarbil后主要终点(首次心衰事件或心血管死亡时间)显著获益(HR 0.80,95%CI 0.71-0.90),而无重度心衰患者无显著获益(HR 0.99,95%CI 0.91-1.08;
要点
- 重度心衰定义为NYHA III-IV级、LVEF≤30%且6个月内因心衰住院。
- Omecamtiv Mecarbil使重度心衰患者主要终点风险降低20%。
- 治疗在重度心衰患者中耐受良好,血压、肾功能和血钾无显著变化。
核心结论
- 在GALACTIC-HF事后分析中,Omecamtiv Mecarbil可能为重度心衰患者带来具有临床意义的复合终点(首次心衰事件或心血管死亡时间)减少。
- 这些数据支持Omecamtiv Mecarbil在现有治疗选择有限的患者中的潜在作用。
研究设计与样本
- GALACTIC-HF为全球双盲、安慰剂对照3期随机临床试验,2017年1月至2020年8月在多中心开展。
- 共纳入8232例有症状心衰(NYHA II-IV级)且左心室射血分数≤35%的患者,按1:1随机接受Omecamtiv Mecarbil或安慰剂,中位随访21.8个月(范围15.4-28.6个月)。
- 本事后分析比较重度心衰患者(2258例,27.4%)与非重度心衰患者。
主要发现
- 重度心衰患者中,Omecamtiv Mecarbil组主要终点显著获益(HR 0.80;95%CI 0.71-0.90)。
- 重度心衰患者中Omecamtiv Mecarbil耐受良好,与安慰剂相比血压、肾功能和血钾无显著变化。
关键数值与推荐
- 重度心衰定义:同时满足NYHA III-IV级、左心室射血分数≤30%、过去6个月内因心衰住院。
临床怎么用
- 对于符合重度心衰定义(NYHA III-IV级、LVEF≤30%、6个月内因心衰住院)的患者,Omecamtiv Mecarbil可能提供额外治疗选择。
- 治疗期间未观察到血压、肾功能或血钾的显著不良变化,支持其在该人群中的耐受性。
局限性
- 本分析为GALACTIC-HF试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Heart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite treatment. Patients with more severe disease are often intolerant of available medical therapies. OBJECTIVE: To evaluate the efficacy and safety of omecamtiv mecarbil for the treatment of patients with severe heart failure (HF) enrolled in the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: The GALACTIC-HF study was a global double-blind, placebo-controlled phase 3 randomized clinical trial that was conducted at multiple centers between January 2017 and August 2020. A total of 8232 patients with symptomatic HF (defined as New York Heart Association symptom class II-IV) and left ventricular ejection fraction of 35% or less were randomized to receive omecamtiv mecarbil or placebo and followed up for a median of 21.8 months (range, 15.4-28.6 months). The current post hoc analysis evaluated the efficacy and safety of omecamtiv mecarbil therapy among patients classified as having severe HF compared with patients without severe HF. Severe HF was defined as the presence of all of the following criteria: New York Heart Association symptom class III to IV, left ventricular ejection fraction of 30% or less, and hospitalization for HF within the previous 6 months. INTERVENTIONS: Participants were randomized at a 1:1 ratio to receive either omecamtiv mecarbil or placebo. MAIN OUTCOMES AND MEASURES: The primary end point was time to first HF event or cardiovascular (CV) death. Secondary end points included time to CV death and safety and tolerability. RESULTS: Among 8232 patients enrolled in the GALACTIC-HF clinical trial, 2258 patients (27.4%; mean [SD] age, 64.5 [11.6] years; 1781 men [78.9%]) met the specified criteria for severe HF. Of those, 1106 patients were randomized to the omecamtiv mecarbil group and 1152 to the placebo group. Patients with severe HF who received omecamtiv mecarbil experienced a significant treatment benefit for the primary end point (hazard ratio [HR], 0.80; 95% CI, 0.71-0.90), whereas patients without severe HF had no significant treatment benefit (HR, 0.99; 95% CI, 0.91-1.08; P = .005 for interaction). For CV death, the results were similar (HR for patients with vs without severe HF: 0.88 [95% CI, 0.75-1.03] vs 1.10 [95% CI, 0.97-1.25]; P = .03 for interaction). Omecamtiv mecarbil therapy was well tolerated in patients with severe HF, with no significant changes in blood pressure, kidney function, or potassium level compared with placebo. CONCLUSIONS AND RELEVANCE: In this post hoc analysis of data from the GALACTIC-HF clinical trial, omecamtiv mecarbil therapy may have provided a clinically meaningful reduction in the composite end point of time to first HF event or CV death among patients with severe HF. These data support a potential role of omecamtiv mecarbil therapy among patients for whom current treatment options are limited. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02929329.
引用
- Felker GM, Solomon SD, Claggett B, et al. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 34643642. doi:10.1001/jamacardio.2021.4027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。